Search

for
Search:

Research

5 / 1000+ results

Alopecia Induced by Tumor Necrosis Factor-Alpha Antagonists: Description of 52 Cases and Disproportionality Analysis in a Nationwide Pharmacovigilance Database

research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database

26 citations , March 2014 in “Rheumatology”

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

research A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

52 citations , January 2005 in “PubMed”

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia

research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia

January 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia

January 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

53 citations , July 2009 in “Cancer Research”

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

View more "alpha-antagonists" in research →

Community Join

5 / 440 results

community Breezula phase 3 results said to be released next month

26 upvotes 1 year ago

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

community Will finasteride halt my beard development ?

in Finasteride/Dutasteride 11 upvotes 2 years ago

Finasteride may slow beard growth but won't stop it. Minoxidil can help increase facial hair coverage.

community I’m trying to find a regimen that works well for me, but maybe my expectations are unrealistic…

2 upvotes 3 weeks ago

The user is seeking a hair loss treatment that doesn't affect beard growth or pose risks to others, using topical finasteride and considering clascoterone and pyrilutamide. They are also using microneedling and ketoconazole shampoo, while avoiding oral finasteride, dutasteride, and minoxidil.

community Reducing Fibrosis in Hair Loss: Topical Pirfenidone

59 upvotes 5 months ago

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

371 upvotes 8 months ago

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

View more "alpha-antagonists" in community →

Learn

5 / 801 results

learn Overview

Clinics

6 / 29 results

All 29 clinic results →

Experts

— no results

Try a deeper search in experts →

Search

for
Search:

Research

research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database

research A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia

research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia

research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

Community Join

community Breezula phase 3 results said to be released next month

community Will finasteride halt my beard development ?

community I’m trying to find a regimen that works well for me, but maybe my expectations are unrealistic…

community Reducing Fibrosis in Hair Loss: Topical Pirfenidone

community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Learn

learn Overview

learn Alpha linolenic acid

learn Alpha Keratin

learn dl-alpha-tocopherol

learn L- Arginine Alpha- Ketoglutarate

Clinics

Experts